From: IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
Age | Gender | Cause of HLH | Underlying immunodeficiency | On-going IS at the onset | H-score/mHLH2009 | Other HLH therapy | Organ supports | HLH response | Relapse | Outcomes | |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 59 | M | Multiple autoimmune disordersa, TMA | Cst | Cst | 248 (99.3%)/7 | DXM, CYC | MV, RRT, VD | CR | No | Alive |
2 | 43 | M | Septicemia | Allogenic SCT | Cst | 220 (96.3%)/5 | No | MV, RRT, VD | CR | No | Death (septic shock; OSL) |
3 | 23 | F | Idiopathic | Heart transplantation | Tacrolimus, MMF, Cst, IVIg | 210 (93%)/5 | No | RRT, VD | CR | No | Alive |
4 | 60 | M | Infections (varicella zoster virus, parvovirus B19, HSV-2), septicemia | Heart transplantation | Tacrolimus, MMF, Cst | 188 (78%)/5 | Etoposide | MV, RRT, VD | None | – | Death (septic shock, aspergillosis, refractory HLH) |
5 | 52 | M | Parvovirus B19 and CAPS | No | No | 208 (92.5%)/5 | IVIg, DXM | MV, RRT, VD | CR | No | Alive |
6 | 53 | M | Idiopathic | Liver transplantation | Tacrolimus, MMF, Cst | 18 (79%)/5 | No | MV, RRT | CR | No | Alive |
7 | 66 | F | Overlap syndrome, TMA | Cst | Cst, rituximab | 186 (75.8%) | DXM | MV, RRT, VD | CR | Yes (etoposide) | Death (gut ischemia; OSL) |
8 | 57 | F | Refractory AIHA | T-LGL, B cell lymphoma | Dxm, CsA, | 188 (78%)/4 | CYC, DXM | MV, RRT, VD | CR | No | Death (septic shock, refractory AIHA) |
9 | 25 | F | S. hominis bacteriemia, HSV-1 | Kidney and liver transplantation | Tacrolimus, MMF, Cst | 218 (95.8%)/6 | No | _ | CR | No | Alive |